Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Update

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 23,500 shares, a growth of 58.8% from the January 15th total of 14,800 shares. Based on an average daily trading volume, of 28,500 shares, the days-to-cover ratio is presently 0.8 days. Approximately 3.6% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Titan Pharmaceuticals in a report on Thursday. They issued a “sell” rating for the company.

Titan Pharmaceuticals Stock Down 1.9 %

Shares of NASDAQ TTNP opened at $4.06 on Friday. The stock has a fifty day moving average price of $3.45 and a two-hundred day moving average price of $4.51. Titan Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.